Proacta SA, operating in a consortium with Euvic SA (leader), is implementing another project in the area of digital transformation of healthcare. The company has received a mutually signed agreement with the Institute of Physiology and Pathology of Hearing based in Warsaw. The project involves the development and implementation of a central IT system supporting diagnostic and therapeutic processes in the field of audiology and genetics.

Project objective
The system being developed aims to integrate audiometric and genetic data of patients with hearing loss. It includes both hardware components and advanced software modules, including user interfaces, classification modules, functional tests, clinical decision support tools, and training and post-implementation services. The solution is designed to optimize diagnostics and provide a personalized therapeutic approach in the field of otolaryngology and clinical genetics.

Significance for Proacta SA
The agreement is valid until March 31, 2026, and its maximum value is PLN 4,907,700.00 gross. Proacta S.A.’s share in the consortium’s remuneration is 98%. Payments will be made in stages, in accordance with the implementation schedule.

The project strengthens Proacta’s position in the segment of modern IT systems for healthcare, using advanced medical data integration and supporting clinical decisions with the use of AI and classification models, which is in line with the company’s long-term strategy for the development of data-driven and AI-based tools for the medical sector.

On June 16, 2025, the Supervisory Board of Proacta S.A. appointed Mr. Mariusz Łukanowski as a member of the Supervisory Board by way of co-optation.

The new member of the Supervisory Board is an experienced manager associated with the IT and modern technology sector. In recent years, he has held management positions at VE Space Sp. z o.o., Databion Sp. z o.o., and Proacta Sp. z o.o., among others.

His experience includes technology development, operational management, and business strategy.
The term of office of the newly appointed member of the Supervisory Board will last until June 30, 2026.
The information required in accordance with NewConnect market regulations, including a personal questionnaire, was provided in EBI’s current report No. 7/2025.

On June 13, 2025, an agreement was signed between Proacta SA, acting in a consortium with Euvic SA based in Gliwice (Consortium Leader), and the University Center for Women’s and Newborn Health of the Medical University of Warsaw sp. z o.o. (“Ordering Party”) based in Warsaw.

The subject of the agreement is the implementation of the project entitled:

“Ultra-early detection of precancerous and cancerous changes in digital colposcopy using artificial intelligence – an opportunity to improve prognosis and increase survival rates for patients with cervical cancer”, financed by the National Recovery and Resilience Plan.

The scope of supplies and works includes:

• 20 research stations (10 notebooks and 10 workstations),
• licenses and access to cloud computing,
• licenses and access to a medical data analysis platform,
• licenses for intelligent diagnostic assistant software,
• design, delivery, and implementation of a Central Information System (CSI) with full transfer of copyrights and source codes.

The agreement will be implemented by March 31, 2026, i.e., within 270 days of its signing, and its total value is PLN 6,826,500.00 gross, of which as much as 98% will go to Proacta S.A.

This is another important step in the development of artificial intelligence-based solutions in medical diagnostics – this time in an area that is crucial for women’s health.

The Management Board of Proacta SA announces that on June 11, 2025, a consortium agreement was signed between Proacta SA, Jan Długosz University in Częstochowa (consortium leader), and the Provincial Specialist Hospital of the Blessed Virgin Mary in Częstochowa.

On the basis of the agreement, on June 13 this year, a joint application was submitted for co-financing of a research and development project as part of the Medical Research Agency’s competition entitled “TRANSMED I – development of R&D projects in the field of translational medicine”.

Project title:

Integrated cardio-oncology platform for the assessment and prediction of cardiotoxicity in oncology patients – i-COPE

Total project cost: PLN 11,425,816.00

Requested funding amount: PLN 10,797,316.00

The project aims to develop a breakthrough solution using artificial intelligence (AI) and advanced machine learning (ML) models to monitor the risk of cardiovascular complications in patients treated for breast cancer.

The aim of the project is to create an online clinical platform that integrates:

• clinical,
• laboratory,
• imaging (including DICOM format),
• oncological, and molecular data.

The resulting tool will enable physicians to quickly and automatically analyze the risk of cardiac complications. As a result, it will be possible to individualize patient care and reduce the risk of discontinuing cancer therapy. The platform will take the form of an interactive risk panel (CDSS), available online and supporting medical decisions.

Proacta SA’s role in the project:

Proacta’s role is crucial. The company is responsible for:

• designing and building the database,
• implementing AI models,
• providing server infrastructure,
• supporting DevOps/MLOps teams, database specialists, and bioinformaticians.

Proacta’s experience in medical data analysis, bioinformatics, and the implementation of medtech solutions will enable the effective implementation of the project’s ambitious goals. i-COPE complements the company’s existing portfolio of digital health solutions, including the Dbam o Siebie Smart LAB platform currently under development.

The project is currently awaiting the results of a formal and substantive evaluation by the Medical Research Agency.

We are pleased to announce that the consortium of Proacta SA and Euvic SA has been selected through an open tender to implement a project for the University Center for Women’s and Newborn Health of the Medical University of Warsaw sp. z o.o.

The project will be implemented as part of the initiative entitled “Ultra-early detection of precancerous and cancerous changes in digital colposcopy using artificial intelligence – an opportunity to improve prognosis and increase survival rates for patients with cervical cancer through effective diagnosis”.

As part of the task, the consortium will provide:

• 20 specialized research stations equipped with appropriate licenses,
• and will create a modern Central Information System (CSI) supporting colposcopic analysis using artificial intelligence.

The value of the contract is PLN 6,826,500.00, of which as much as 98% will go to Proacta SA. The contract will be implemented within 270 days from the date of signing.

This is another step towards the use of the latest technologies in medicine and confirmation of Proacta SA’s competence in creating IT solutions for the healthcare sector. The project has the potential to have a real impact on the effectiveness of cervical cancer diagnosis and improve the prognosis for patients across the country.